CEGE Jetzt einsteigen - 500 Beiträge pro Seite

[therman]

CEGE strong buy.http://bigcharts.marketwatch.com/javachart/javachart.asp?sym…" target="_blank" rel="nofollow ugc noopener">

http://bigcharts.marketwatch.com/javachart/javachart.asp?sym…


http://finance.yahoo.com/q/mh?s=CEGE

Homepage:http://www.cellgenesys.com/home.shtml

Bin heute eingestiegen heute zu: 5,75$.
Werde weiter zukaufen.
langfristig ein verfielfacher.

Einschätzung von multex360.com:
INVESTMENT CONCLUSION
After our recent discussions with management, we have increased confidence in the design and conduct of the current Phase 3 trials
for GVAX prostate cancer vaccine as well as the scientific basis for the cancer vaccine platform overall. The managerial and financial
resources of the company have been enhanced by the new additions of Rob Dow (SVP Medical Affairs) and Sharon Tetlow (CFO) to help
address the challenge of moving the clinical products forward (5 products in clinical testing) as well as the potential for licensing of the
antibody production technology, other non-core assets, and product pipeline partnership to help address the cash position (approximately two
years of cash).
We believe the next six months will show continued progress, as we await data from the Phase 2 trial for GVAX pancreatic cancer vaccine
in operable pancreatic cancer and Phase 2 data for GVAX vaccine in AML. We therefore reiterate our Strong Buy Rating. Our 12-
month target price of $14 is based on a P/E multiple of 30x and our 2010 EPS estimate, to which we apply a 30% annual discount
rate.


therman

[cyberhai]

Hier die Pipeline:

http://www.cellgenesys.com/clinical-stage.shtml

Gruß Cyberhai

[cyberhai]

Die letzten Analysen (bei Comdirect):

Analysten-Bewertung - 19.08.05
Cell Genesys spekulativer Kauf

Für die Experten vom Biotech-Report ist die Aktie von Cell Genesys (/ ) ein spekulativer Kauf. Anfang Juli sei der Wert von den Analysten von Infinium Capital mit einem Kursziel von 12 USD empfohlen worden. Dabei hätten sie in ihrer Studie heraus gestellt, dass die Gesellschaft mit Gvax einen wichtigen Impfstoff zur Behandlung von Krebs in der Produktpipeline habe. Das US-Biotechunternehmen habe am 25. Juli seine Zahlen für das zweite Quartal 2005 veröffentlicht. Demnach sei ein Umsatz in Höhe von 2,78 Mio. USD und ein Verlust in Höhe von 0,58 USD je Aktie gemeldet worden. Der Cashbestand habe bei 121 Mio. USD gelegen. Die Aktie von Cell Genesys ist für die Experten vom "Biotech-Report" ein spekulativer Kauf.


Analysten-Bewertung - 20.06.05
Cell Genesys kaufen

Die Experten von "Global Biotech Investing" empfehlen die Aktie von Cell Genesys (/ WKN 888140) zum Kauf. Der Biotech-Konzern habe in der vorletzten Woche die Entlassung von 95 Mitarbeitern (25% der gesamten Angestellten) und die Einstellung von drei Forschungsprogrammen bekannt gegeben. Dadurch erhoffe man sich eine Konstenersparnis von 12 - 15 Mio. USD pro Jahr. Zudem solle die Konzentration auf das verbliebene bereits in Phase III befindliche GVAX Prostatakrebs-Programm verstärkt werden. Die Ankündigungen habe der Markt positiv aufgenommen. Aus fundamentaler Sicht stehe das Unternehmen gut da. Die Analysten seien sich bei kaum einem anderen Wert so über das dreistellige Potenzial einig wie bei Cell Genesys. Durch einen Cash-Bestand von satten 145 Mio. USD sei der aktuelle Börsenwert von 240 Mio. USD zu mehr als der Hälfte abgedeckt. Hinzu komme das Paket von 6,6 Mio. ABGENIX-Aktien im aktuellen Marktwert von 46 Mio. USD. In der zweiten Jahreshälfte 2008 werde die Markteinführung des GVAX Prostatakrebs-Impfstoffs erwartet. Cell Genesy werde wahrscheinlich im Jahr 2009 oder sogar erst 2010 in die Gewinnzone vorstoßen können. Zwar schrecke dieser Zeithorizont vorerst ab. Doch dabei werde übersehen, dass das Produkt- und Ertragspotenzial von den Analysten einhellig als geradezu phantastisch dargestellt werde. Schließlich werde allein das Marktpotenzial des GVAX Prostatakrebs-Impfstoffs auf knapp 3 Mrd. USD geschätzt. Zudem dürfe auch nicht das GVAX-Impfstoff-Programm gegen Leukämie vergessen werden, dem würden Analysten im Erfolgsfall einen Markt von 1,5 Mrd. USD zugestehen. Gleich vier US-Investmenthäuser seien der Ansicht, dass Cell Genesys eigentlich das Doppelte des aktuellen Niveaus kosten müsste. Analysten würden für den Biotech-Wert Kursziele von 9 USD bis sogar 14 USD sehen. Auch wenn sich der Kurs nach der Bekanntgabe der Restrukturierungspläne vor ein paar Wochen von 4,35 USD auf aktuell 5,50 USD bereits kräftig erholt habe, so biete die Aktie wegen der einhelligen Analystenstimmung eine ausgezeichnete Chance auf steuerfreie dreistellige Gewinne auf 12-Monatssicht. Mit einem Stoppkurs bei 5,25 USD empfehlen die Experten von "Global Biotech Investing" die Cell Genesys-Aktie erneut zum Kauf.


Gruß Cyberhai

[Diavolo666]

Cell Genesys Reports Positive Results From Phase 2 Trial of GVAX(R) Vaccine for Leukemia in Chronic Myelogenous Leukemia



Vaccine Reduces Molecular Evidence of Persistent Leukemia After Long-Term
Gleevec(R) Therapy
ATLANTA, Dec. 12 /PRNewswire-FirstCall/ -- Cell Genesys, Inc. (Nasdaq: CEGE) today reported encouraging clinical data from a Phase 2 trial of GVAX(R) vaccine for chronic myelogenous leukemia (CML). Nineteen CML patients with molecular evidence of persistent leukemia despite more than one year of Gleevec(R) (imatinib mesylate) therapy were treated with GVAX vaccine for leukemia while continuing to receive Gleevec. The initial findings of this trial indicate that the addition of the vaccine to Gleevec therapy has reduced persistent leukemic disease in 9 of 19 patients to date as demonstrated by a complete disappearance (five patients) or a greater than one log (90%) reduction (four patients) in bcr-abl -- a validated genetic marker found on the leukemic cells. Of the remaining 10 patients, only one patient has progressed on therapy with GVAX vaccine for leukemia while the other 9 continue to be monitored for reductions in bcr-abl. Reductions of bcr-abl have been previously shown to be strongly associated with improved progression-free survival in patients with CML. The trial was conducted at the Johns Hopkins Sidney Kimmel Comprehensive Cancer Center by Dr. Hyam Levitsky, professor of Oncology Medicine and Urology, and colleagues, and the data were presented today at the annual meeting of the American Society of Hematology (ASH) in Atlanta, GA (ASH Abstract #2858).

The Phase 2 trial enrolled 19 patients with chronic phase CML. All patients had detectable bcr-abl levels at study entry as measured by a PCR (polymerase chain reaction) assay despite having received at least one year of Gleevec therapy. The median duration of Gleevec therapy prior to study entry was three years. Patients were treated with four injections of GVAX vaccine for leukemia at three-week intervals over a total treatment period of nine weeks. Treatment was well tolerated and all patients completed all four planned treatments. As noted above, to date 9 of the 19 patients have achieved molecular responses after the four treatments as defined by either a complete disappearance or greater than one log (90%) reduction in bcr-abl, and 9 of the remaining 10 patients continue to be monitored for reductions in bcr- abl. In addition, the decline in mean bcr-abl levels from pre- to post- treatment with GVAX vaccine for leukemia was statistically significant (p=0.03). Despite the fact that patients were treated with GVAX vaccine for leukemia for only nine weeks and did not receive booster injections, the molecular responses are ongoing in seven of nine patients with a median response duration at this point in the study of greater than five months.

"We are certainly encouraged by the results to date from this Phase 2 trial in CML, in particular by the induction of molecular responses in patients with persistent leukemic disease despite one or more years of Gleevec therapy," stated Joseph J. Vallner, Ph.D., president and chief operating officer of Cell Genesys. "Based on these findings, we plan to continue to analyze the results from this ongoing trial with the goal of discussing a potential product registration strategy with the Food and Drug Administration (FDA)."

The therapy of CML has improved substantially in recent years as a result of the introduction of Gleevec therapy, which is now approved for the first- line treatment of CML in chronic phase. Hematologic responses are seen routinely in the majority of treated patients but complete molecular responses, as measured by quantitative PCR for bcr-abl, occur in less than 10 percent of patients even after 12 months of therapy. Given that the reduction in bcr-abl in patients is positively associated with clinical outcome, new therapeutic strategies to eliminate persistent leukemic disease as evidenced by bcr-abl positive cells are urgently needed. Moreover, it should be noted that to date, the only therapeutic intervention shown to be capable of completely eliminating bcr-abl positive leukemic cells in the majority of patients is allogeneic bone marrow transplantation, an intensive medical procedure with significant treatment-related mortality that may not be indicated in many patients.

Clinical trials of GVAX cancer vaccines are under way for multiple types of cancer including, in addition to leukemia, prostate cancer and pancreatic cancer. GVAX vaccines are designed to stimulate an immune response against the patient`s tumor. The vaccines are comprised of tumor cells that have been genetically modified to secrete GM-CSF, an immune stimulatory hormone that plays a key role in stimulating the body`s immune response to vaccines and are being developed as non patient-specific "off-the-shelf" pharmaceutical products. GVAX cancer vaccines have demonstrated a favorable side effect profile in over 600 patients treated in clinical trials to date.

Cell Genesys is focused on the development and commercialization of novel biological therapies for patients with cancer. The company is currently pursuing two clinical stage product platforms -- GVAX(R) cancer vaccines and oncolytic virus therapies. Ongoing clinical trials include Phase 3 trials of GVAX vaccine for prostate cancer, Phase 2 trials of GVAX vaccines for leukemia and pancreatic cancer, and a Phase 1 trial of CG0070 oncolytic virus therapy for bladder cancer and potentially other types of cancer. Cell Genesys continues to hold equity interests in its two former subsidiaries -- Abgenix, Inc., an antibody products company and Ceregene, Inc., which is developing gene therapies for neurodegenerative disorders. Cell Genesys is headquartered in South San Francisco, CA and has its principal manufacturing operation in Hayward, CA. For additional information, please visit the company`s website at www.cellgenesys.com.

Statements made herein about the company, other than statements of historical fact, including statements about the company`s progress, results and timing of clinical trials and pre-clinical programs and the nature of product pipelines are forward-looking statements and are subject to a number of uncertainties that could cause actual results to differ materially from the statements made, including risks associated with the success of clinical trials and research and development programs, the regulatory approval process for clinical trials, competitive technologies and products, patents, continuation of corporate partnerships and the need for additional financings. For information about these and other risks which may affect Cell Genesys, please see the company`s Annual Report on Form 10-K for the year ended December 31, 2004 dated March 14, 2005 as well as Cell Genesys` reports on Form 10-Q and 8-K and other reports filed from time to time with the Securities and Exchange Commission. The company assumes no obligation to update the forward-looking information in this press release.


Contact: Ina Cu
Investor Relations
Cell Genesys, Inc.
650-266-3200

[cyberhai]

bizjournals.com
UC testing vaccine for prostate cancer
Tuesday February 14, 10:05 am ET

A University of Cincinnati researcher is among scientists across North America testing a vaccine to stimulate the immune system to fight prostate cancer.

Dr. Leslie Oleksowicz, a medical oncologist, is leading local testing in the Phase 3 clinical trial, which will determine whether the vaccine can increase survival for patients whose disease has spread and stopped responding to hormone therapy.

Hormone therapy prevents the body from making or using androgen, a male hormone linked to the growth of certain prostate cancer cells. The treatment decreases hormone levels and slows cancer growth.

"We regularly use hormone therapy to treat men with advanced prostate cancer, but unfortunately it doesn`t work forever," said Oleksowicz, director of UC`s medical genitourinary oncology program. "Cells that don`t need androgen to grow will eventually take over and begin to spread."

Researchers believe that the vaccine, called VITAL-1, may stop tumor growth without decreasing the patient`s quality of life.

"Tumors invade the immune system by producing antigens that trick the body into tolerating them," Oleksowicz said. "Our hope is that this vaccine will `jump start` the immune system to fight off the tumor."

Previous clinical trials evaluating a similar prostate cancer vaccine suggested it could potentially provide a more beneficial and less toxic alternative to chemotherapy.

Researchers from about 70 medical centers are recruiting 600 men with adenocarcinoma, a type of cancer that begins in the lining of certain internal organs and can spread through the body`s glandular system. Patients who have been treated with chemotherapy, gene therapy or immunotherapy are not eligible.

Study participants will be randomized into one of two treatment groups. The first group will receive the investigational prostate cancer vaccine every two weeks for a total of 13 vaccinations. The second will get chemotherapy (docetaxel and prednisone) every three weeks.

According to the American Cancer Society, more than 230,000 new cases of prostate cancer were diagnosed in 2005. The disease annually results in about 30,000 deaths in the United States, making it the second leading cause of cancer-related death among men. When detected in an early stage, prostate cancer is one of the most curable types of the disease.

[bradetti]

Hallo?!

Also wenn das kein aussichtsreiches Unternehmen ist, dann weiß ich auch nicht, und der Chart sieht seeeeehr reizvoll aus



Gruß an unbekannt
Bradetti

[bradetti]

Aktuelles

SOUTH SAN FRANCISCO, Calif. (AP) -- Shares of Cell Genesys Inc. received a boost Wednesday after the biotech company said the Food and Drug Administration gave its prostate cancer treatment candidate a fast track designation.

Cell Genesys shares rose 36 cents, or 5.6 percent, to $6.83 in morning trading on the Nasdaq. The stock has traded between $4.39 and $8.10 over the past 52 weeks.

The company is enrolling advanced prostate cancer patients in two late-stage clinical trials to test the effectiveness of its GVAX cancer treatment. With a fast track designation, Cell Genesys will be able to submit data to the FDA as it becomes available rather than having to wait and submit it all at once.

In one trial, Cell Genesys said it plans to enroll 600 patients without pain or symptoms who have never received cancer treatment before. The trial will compare GVAX to Sanofi-Aventis SA's Taxotere chemotherapy plus the steroid prednisone.

In the other trial, 600 patients with cancer-related pain and symptoms will be enrolled. Patients will be given either GVAX plus Taxotere, or Taxotere and prednisone.

Both trials will test whether GVAX improves patient survival.

Naja, det looft...